MX2012007326A - Polivinilpirrolidona para la estabilizacion de una dispersion solida de forma no cristalina de rotigotina. - Google Patents
Polivinilpirrolidona para la estabilizacion de una dispersion solida de forma no cristalina de rotigotina.Info
- Publication number
- MX2012007326A MX2012007326A MX2012007326A MX2012007326A MX2012007326A MX 2012007326 A MX2012007326 A MX 2012007326A MX 2012007326 A MX2012007326 A MX 2012007326A MX 2012007326 A MX2012007326 A MX 2012007326A MX 2012007326 A MX2012007326 A MX 2012007326A
- Authority
- MX
- Mexico
- Prior art keywords
- rotigotine
- polyvinylpyrrolidone
- solid dispersion
- crystalline form
- stabilization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente invención se refiere a un método para estabilizar rotigotina, comprendiendo el método proporcionar una dispersión sólida comprendiendo polivinilpirrolidona y una forma no cristalina de rotigotina, en donde la proporción en peso de rotigotina a polivinilpirrolidona está en un rango desde aproximadamente 9:3.5 hasta aproximadamente 9:6. La presente invención también se refiere a una dispersión sólida comprendiendo un agente dispersante y una fase dispersa, comprendiendo dicha fase dispersa rotigotina y polivinilpirrolidona, en donde la proporción en peso de rotigotina a polivinilpirrolidona está en un rango desde aproximadamente 9:3.5 hasta aproximadamente 9:6, una composición farmacéutica comprendiendo tal dispersión sólida, en particular un sistema terapéutico transdérmico, así como un método para la preparación del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28930209P | 2009-12-22 | 2009-12-22 | |
PCT/EP2010/070563 WO2011076879A1 (en) | 2009-12-22 | 2010-12-22 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012007326A true MX2012007326A (es) | 2012-08-01 |
Family
ID=43568293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007326A MX2012007326A (es) | 2009-12-22 | 2010-12-22 | Polivinilpirrolidona para la estabilizacion de una dispersion solida de forma no cristalina de rotigotina. |
Country Status (25)
Country | Link |
---|---|
US (4) | US9925150B2 (es) |
EP (2) | EP2515887B1 (es) |
JP (1) | JP5815556B2 (es) |
KR (3) | KR20160055971A (es) |
CN (3) | CN102665699A (es) |
AU (1) | AU2010334805B2 (es) |
BR (1) | BR112012017737A8 (es) |
CA (1) | CA2767068C (es) |
CY (1) | CY1120621T1 (es) |
DK (1) | DK2515887T3 (es) |
EA (1) | EA025584B1 (es) |
ES (1) | ES2679800T3 (es) |
HK (1) | HK1200335A1 (es) |
HR (1) | HRP20181173T1 (es) |
HU (1) | HUE039447T2 (es) |
IL (1) | IL219091A (es) |
LT (1) | LT2515887T (es) |
ME (1) | ME03053B (es) |
MX (1) | MX2012007326A (es) |
PL (1) | PL2515887T3 (es) |
PT (1) | PT2515887T (es) |
RS (1) | RS57457B1 (es) |
SI (1) | SI2515887T1 (es) |
TR (1) | TR201810322T4 (es) |
WO (1) | WO2011076879A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
NZ584363A (en) * | 2007-11-28 | 2012-11-30 | Ucb Pharma Gmbh | Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2 |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
BR112012017737A8 (pt) | 2009-12-22 | 2018-04-17 | Lts Lohmann Therapie Systeme Ag | polivinilpirrolidona para a estabilização de uma dispersão sólida da forma não cristalina de rotigotina. |
WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
DE102011119043A1 (de) | 2011-11-22 | 2013-05-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TDS) mit Rotigotin |
WO2013075822A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system (tts) with rotigotine |
DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
DE102011090178A1 (de) | 2011-12-30 | 2013-07-04 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation |
MX2015000049A (es) | 2012-07-05 | 2015-04-08 | Sk Chemicals Co Ltd | Preparacion absorbible transdermicamente que contiene rotigotina. |
KR101558043B1 (ko) * | 2012-07-06 | 2015-10-07 | 에스케이케미칼주식회사 | 로티고틴 함유 경피흡수제제 |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
EP3016641B1 (de) | 2013-07-03 | 2018-09-05 | LTS Lohmann Therapie-Systeme AG | Transdermales therapeutisches system mit elektronischem bauteil |
JP6895755B2 (ja) * | 2014-05-20 | 2021-06-30 | エルテーエス ローマン テラピー−ジステーメ アーゲー | 経皮送達システムにおける活性薬剤の放出を調節するための方法 |
EP3145504B1 (en) * | 2014-05-20 | 2023-07-26 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system including an interface mediator |
US11633367B2 (en) | 2014-05-20 | 2023-04-25 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
KR102364378B1 (ko) * | 2014-05-21 | 2022-02-16 | 에스케이케미칼 주식회사 | 안정성을 향상시킨 로티고틴 함유 경피흡수제제 |
DE102014114282A1 (de) * | 2014-10-01 | 2016-04-07 | Neuraxpharm Arzneimittel Gmbh | Transdermales therapeutisches System mit Rotigotin zur Behandlung von Morbus Parkinson |
CN104382850B (zh) * | 2014-10-17 | 2017-12-22 | 烟台大学 | 一种罗替戈汀微乳及微乳凝胶 |
US20210100754A1 (en) * | 2016-02-05 | 2021-04-08 | 3M Innovative Properties Company | Transdermal drug delivery systems with fluorosilicone release liners |
JP7178072B2 (ja) * | 2017-02-03 | 2022-11-25 | コスメディ製薬株式会社 | ロチゴチン含有経皮吸収型貼付剤 |
BR112020003314A2 (pt) * | 2017-09-04 | 2020-08-25 | Lts Lohmann Therapie-Systeme Ag | sistema de liberação transdérmico incluindo um emulsificante |
WO2019124261A1 (ja) | 2017-12-19 | 2019-06-27 | 久光製薬株式会社 | ロチゴチン含有貼付剤 |
KR20200046461A (ko) * | 2018-10-24 | 2020-05-07 | 에스케이케미칼 주식회사 | 비결정 로티고틴 함유 조성물 및 이의 제조 방법 |
WO2020166298A1 (ja) | 2019-02-15 | 2020-08-20 | 久光製薬株式会社 | ロチゴチン安定化方法 |
BR112022012111A2 (pt) * | 2019-12-20 | 2022-08-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapêutico transdérmico contendo agomelatina |
PL3854388T3 (pl) | 2020-01-24 | 2024-02-26 | Luye Pharma Switzerland Ag | Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin |
CN112089686A (zh) * | 2020-10-12 | 2020-12-18 | 郑鉴忠 | 游离药物黏膜皮肤给药制剂生产方法 |
WO2024040860A1 (zh) * | 2022-08-24 | 2024-02-29 | 新领医药技术(深圳)有限公司 | 抑制结晶的罗替高汀透皮给药系统及其制备方法和用途 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177112A (en) | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5308887A (en) * | 1991-05-23 | 1994-05-03 | Minnesota Mining & Manufacturing Company | Pressure-sensitive adhesives |
US5676968A (en) | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
US5989586A (en) | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
US5382596A (en) | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
US6713300B1 (en) * | 1997-02-27 | 2004-03-30 | University Of Utah Research Foundation | Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
ES2216992T3 (es) | 1999-11-23 | 2004-11-01 | Aderis Pharmaceuticals, Inc. | Procedimiento mejorado para la preparacion de aminotetralinas nitrogeno-substituidas. |
LU90623B1 (en) | 2000-08-04 | 2002-02-05 | Trefilarbed Bissen Sa | Method and installation for coating wire material |
DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
EP1256339B1 (en) | 2001-05-08 | 2003-10-15 | Schwarz Pharma Ag | Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
ES2203563T3 (es) | 2001-05-08 | 2004-04-16 | Schwarz Pharma Ag | Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson. |
US20030026830A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
US20060263419A1 (en) | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
EP1494664A2 (en) | 2002-04-18 | 2005-01-12 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
DE10220230A1 (de) * | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
US20040048779A1 (en) | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US20060216336A1 (en) | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
CA2491313C (en) * | 2002-07-15 | 2011-05-24 | Alcon, Inc. | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
EP1386604A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system |
US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
EP1386605A1 (en) * | 2002-07-30 | 2004-02-04 | Schwarz Pharma Ag | Improved transdermal delivery system for the administration of rotigotine |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
DK1426049T3 (da) | 2002-12-02 | 2005-08-22 | Sanol Arznei Schwarz Gmbh | Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
DE10334187A1 (de) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361259A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
US20050197385A1 (en) | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
TWI392670B (zh) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
US20080226698A1 (en) | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
EP1987815A1 (en) | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
CN101147739B (zh) * | 2007-07-06 | 2010-12-08 | 北京康倍得医药技术开发有限公司 | 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂 |
DE502007002833D1 (de) | 2007-11-27 | 2010-03-25 | Delphi Tech Inc | Vorrichtung und Verfahren zum Falten eines Luftsacks |
NZ584363A (en) | 2007-11-28 | 2012-11-30 | Ucb Pharma Gmbh | Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2 |
US20090202647A1 (en) * | 2008-02-11 | 2009-08-13 | Mayur Devjibhai Khunt | Solid form of racemic rotigotine |
MX2010012989A (es) * | 2008-05-30 | 2011-04-27 | Mylan Inc | Sistema de suministro de farmaco transdermico estabilizado. |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
BR112012017737A8 (pt) | 2009-12-22 | 2018-04-17 | Lts Lohmann Therapie Systeme Ag | polivinilpirrolidona para a estabilização de uma dispersão sólida da forma não cristalina de rotigotina. |
-
2010
- 2010-12-22 BR BR112012017737A patent/BR112012017737A8/pt not_active Application Discontinuation
- 2010-12-22 ES ES10796399.3T patent/ES2679800T3/es active Active
- 2010-12-22 MX MX2012007326A patent/MX2012007326A/es unknown
- 2010-12-22 LT LTEP10796399.3T patent/LT2515887T/lt unknown
- 2010-12-22 SI SI201031744T patent/SI2515887T1/sl unknown
- 2010-12-22 US US13/515,067 patent/US9925150B2/en active Active
- 2010-12-22 ME MEP-2018-184A patent/ME03053B/me unknown
- 2010-12-22 WO PCT/EP2010/070563 patent/WO2011076879A1/en active Application Filing
- 2010-12-22 CA CA2767068A patent/CA2767068C/en active Active
- 2010-12-22 CN CN2010800513394A patent/CN102665699A/zh active Pending
- 2010-12-22 HU HUE10796399A patent/HUE039447T2/hu unknown
- 2010-12-22 KR KR1020167011866A patent/KR20160055971A/ko not_active Application Discontinuation
- 2010-12-22 EA EA201270657A patent/EA025584B1/ru not_active IP Right Cessation
- 2010-12-22 PL PL10796399T patent/PL2515887T3/pl unknown
- 2010-12-22 KR KR1020167025041A patent/KR20170023772A/ko not_active Application Discontinuation
- 2010-12-22 KR KR1020127016095A patent/KR101807721B1/ko active IP Right Grant
- 2010-12-22 EP EP10796399.3A patent/EP2515887B1/en active Active
- 2010-12-22 DK DK10796399.3T patent/DK2515887T3/en active
- 2010-12-22 EP EP17185284.1A patent/EP3257504A1/en active Pending
- 2010-12-22 TR TR2018/10322T patent/TR201810322T4/tr unknown
- 2010-12-22 RS RS20180850A patent/RS57457B1/sr unknown
- 2010-12-22 CN CN201610412864.3A patent/CN105997952A/zh active Pending
- 2010-12-22 PT PT10796399T patent/PT2515887T/pt unknown
- 2010-12-22 JP JP2012545332A patent/JP5815556B2/ja active Active
- 2010-12-22 AU AU2010334805A patent/AU2010334805B2/en active Active
- 2010-12-22 CN CN201410448874.3A patent/CN104189912A/zh active Pending
-
2012
- 2012-04-05 IL IL219091A patent/IL219091A/en active IP Right Grant
-
2015
- 2015-01-23 HK HK15100819.2A patent/HK1200335A1/xx unknown
-
2018
- 2018-01-31 US US15/884,587 patent/US10130589B2/en active Active
- 2018-05-17 US US15/982,744 patent/US10350174B2/en active Active
- 2018-07-20 HR HRP20181173TT patent/HRP20181173T1/hr unknown
- 2018-08-24 CY CY181100885T patent/CY1120621T1/el unknown
-
2019
- 2019-05-23 US US16/420,501 patent/US20190314294A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012007326A (es) | Polivinilpirrolidona para la estabilizacion de una dispersion solida de forma no cristalina de rotigotina. | |
MX2015007710A (es) | Indanilcarboxamidas difluorometil-nicotinicas. | |
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
UA104869C2 (uk) | Фармацевтичні композиції, що містять ліганди рецептора дофаміну | |
MX354543B (es) | Composicion esterilizada que comprende al menos un acido hialuronico y ascorbilo fosfato de magnesio. | |
EA201291306A1 (ru) | Состав сухого порошка, содержащий антимускариновое средство | |
MX2014013570A (es) | Pirazol indanil carboxamidas. | |
TN2011000282A1 (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
MY156332A (en) | Quinuclidine carbonate derivatives and medicinal composition thereof | |
MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
MX2010006259A (es) | Piperazinas como agentes antiobesidad. | |
IN2014DN09416A (es) | ||
MY148772A (en) | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | |
MX2010006215A (es) | Derivados de piperazina y su uso como moduladores del receptor de leptina. | |
WO2011139249A3 (en) | Pharmaceutical composition comprising cefdinir | |
MX2010006216A (es) | Nuevos compuestos iii. | |
MX2015007488A (es) | Composicion farmaceutica oftalmologica topica que contiene regorafenib. | |
WO2011119649A3 (en) | Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs | |
RS53835B1 (en) | PHARMACEUTICAL COMPOSITION WITH ANTIMICROBIC ACTION AND FOR ACCELERATED HEALING, FOR EXTERNAL ADMINISTRATION, PROCESSES FOR ITS ACQUISITION | |
WO2010101538A3 (en) | New crystalline forms of tiotropium bromide | |
MX2014013498A (es) | Analogos hexadepsipeptidos como compuestos anticancerigenos. | |
WO2012007758A3 (en) | Pharmaceutical formulations | |
MX2010006220A (es) | Derivados de morfolina como agentes antiobesidad. | |
MX2012008861A (es) | Composicion farmaceutica con actividad antiobesidad que comprende una premezcla de orlistat puro y proceso de preparacion. | |
TW201129660A (en) | Dermal absorption agent comprising felbinac |